01 — At a Glance
The Biotech Unicorn Factory That Just Went Public
- IPO Price (July 2025)₹355
- CMP (March 2026)₹636
- 52-Week High / Low₹874 / ₹579
- TTM Revenue₹1,997 Cr
- TTM EPS₹8.64
- Book Value₹49.0
- Price to Book13.0x
- Dividend Yield0.00%
- Debt / Equity0.04x
- OPM (TTM)38.2%
The IPO Glow Still Hasn’t Faded: Anthem Biosciences — a Contract Research, Development, and Manufacturing Organization (CRDMO) — went public in July 2025 at ₹355 per share. Eight months later, the stock sits at ₹636, a 79% gain in a year when Nifty 500 barely groaned. Q3 FY26 revenue hit ₹423 crore (down 15% YoY), PAT ₹111 crore, EPS ₹1.65. TTM P/E: 71x. TTM EPS: ₹8.64. That’s not valuation, that’s faith. But wait — the concall hinted at structural margin improvements, GLP-1 upside, and a ₹1,000 crore capex for Unit-4 that could triple capacity by FY28. This is either the next mega-cap biotech outfit or a Darling IPO that forgot to do the math.
02 — Introduction
The Invisible Hands Behind India’s Biotech Pills
Anthem Biosciences doesn’t make drugs. It makes drugs for companies that make drugs. When Novo Nordisk wanted to scale semaglutide (Ozempic, Wegovy — the weight-loss pandemic drug), they needed a CRDMO. When a small American biotech discovered a breakthrough cancer therapeutic and needed someone to make clinical trial batches, they called Anthem. When GSK or Eli Lilly needed contract manufacturing of an active pharmaceutical ingredient, Anthem was already there.
This is the glamourless, unglamorous, genuinely unglamorous business of Contract Research, Development, and Manufacturing. No brand recall. Zero consumer visibility. And yet — it’s one of the most mission-critical functions in global pharma. A single failed manufacturing batch doesn’t just cost money; it delays human trials. It costs lives. The stakes are absurd. The margins are absurd. And the visibility is nonexistent.
Incorporated in 2006, Anthem has spent two decades building three manufacturing plants, hiring 2,062 scientists and engineers, and developing proprietary platforms in RNA interference (RNAi), Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides. In FY24, it executed 8,000+ unique customer programs with 675+ clients globally. In FY25, it manufactured APIs and advanced intermediates for 10 commercialized molecules — five of the top six revenue-generating molecules in their respective markets. Last year, it went public at ₹355. Today, it trades at ₹636. And it’s just getting started.
Concall Highlight (Feb 2026): “We have added more than one large customer… many of them are at development stage, some products already approved and going into the market.” — Management. Translation: Blockbuster drugs are about to scale, and Anthem will be the manufacturing backbone. The revenue impact hasn’t hit yet, but the pipeline is gorging.
03 — Business Model: Making Millionaires, One Molecule at a Time
They Don’t Discover. They Manufacture. They’re Better at It Than You Think.
The CRDMO model is beautifully simple. A biotech discovers a promising drug. Phase 1 trials require milligrams. They call Anthem. Phase 2 requires grams. Still Anthem. Phase 3 requires kilograms. Phase 3 clinical trials run 2-5 years. Anthem becomes their exclusive manufacturing partner, often the only facility in the world capable of producing that particular molecule at scale. When the drug is approved and hits the market, Anthem ramps to commercial volumes — sometimes overnight. A single commercial molecule can generate ₹50–200 crore in annual revenue for years.
But here’s the catch: drug development is lumpy as hell. A Phase 3 trial can fail. A molecule can get rejected by regulators. The entire revenue stream evaporates overnight. Anthem’s business model is therefore not “X drug will generate Y revenue”; it’s “we’ll work with 200+ companies, develop 1,000+ molecules, 5-10% will succeed, and those 50-100 winners will fund our entire operation.” Diversification by sheer volume.
Anthem operates three manufacturing plants: Unit I (Bommassandra) with 24 kL custom synthesis + 2 kL fermentation; Unit II (Harohalli) with 270 kL custom synthesis (expanded from 152 kL in FY23) + 142 kL fermentation; Unit III (Harohalli) under construction, expected H1 FY26. A ₹1,000 crore Unit IV greenfield is also in the pipeline — civil works underway, major capex expected FY27-28. Fermentation capacity (for biologics like peptides, probiotics, biosimilars) is currently 46-47% utilized. Custom synthesis is 75% utilized across existing units. Translation: room to grow without immediately adding brick-and-mortar.
CRDMO Revenue₹1,260 Cr9M FY26 (66%)
Specialty Ingredients₹254 Cr9M FY26 (34%)
Customers Served550+Global, 44+ countries
Top Customer Conc.~24%FY25 revenue
Module Breakdown (9M FY26): R&D (10.87%), Development & Manufacturing (70.78%), Specialty Ingredients (18.75%). Geographic split: Europe 54.6%, North America 26.4%, India 16.6%, Rest of Asia 2.4%. The company is essentially a contract manufacturer for Western pharma that happens to be based in Bangalore. Arbitrage: Indian cost structure, global quality standards, and first-mover advantage in niche biologics.
💬 If drug discovery is a lottery with 1-in-5,000 odds, and Anthem works with 200+ companies, why doesn’t the market price it as a pure lottery? Drop a thought in the comments.
04 — Financials Overview
Q3 FY26: The Numbers (And Why They Matter Less Than You’d Think)
Result type: Quarterly Results | Q3 FY26 EPS: ₹1.65 | Annualised EPS (Q3×4): ₹6.60 | TTM EPS: ₹8.64
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 423 | 498 | 550 | -15.0% | -23.1% |
| Operating Profit | 157 | 160 | 218 | -1.9% | -28.0% |
| OPM % | 37% | 32% | 40% | +500 bps | -300 bps |
| PAT | 93 | 124 | 173 | -25.0% | -46.2% |
| EPS (₹) | 1.65 | 2.22 | 3.09 | -25.7% | -46.6% |
Wait, Revenue Down 15% YoY? Prepare for the Excuse Salad: Management blamed “higher base” (Q3 FY25 was an anomaly), global customer destocking, and geopolitical anxiety. They also cited a “recovery” underway with RFQ requests picking up. Translation: Q3 was a down quarter in a lumpy business. Q2 was a peak. Q4 seasonally strong. This is the CRDMO business in real time — volatile, lumpy, revenue-wise unpredictable, but margin-wise stable. The stock fell only 3.8% on these numbers because analysts care more about the ₹1,000 crore Unit-4 capex story (which is 18 months away) than Q3 results (which are already baked in).
05 — Valuation: The Danger Zone
Is 71x P/E Justified, or Did IPO Investors Just FOMO-Buy a Lottery Ticket?
Join 10,000+ investors who read this every week.
